Riskpilot← Back to searchSign inGet full access2care4 AB
ABActiveOrg 5568920614Olof Palmes Gata 11Manufacture of pharmaceutical preparations · NACE 2120Est. 20125 employees
Revenue 2025
SEK 8,9M
+3% vs 2024
EBITDA margin
15.1%
+176% vs 2024
Equity ratio
75.5%
Financial strength
Net profit 2025
SEK 1,1M
+164% vs 2024
| Revenue | SEK 8,9M | +3% |
| EBITDA | SEK 1,4M | +176% |
| Net profit | SEK 1,1M | +164% |
| Total assets | SEK 4,9M | +32% |
| Equity | SEK 3,7M | +43% |
| Employees | 5 | — |
Legal name
2care4 AB
Org number
5568920614
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
2 maj 2012
Share capital
SEK 50 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva import, produktion, export och föräljning av läkemedel samt bedriva därmed förenlig verksamhet.
Address
Olof Palmes Gata 11
Email
dwi@2care4.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 4 670 | 5 461 | 7 030 | 6 060 | 6 681 | 9 480 | 8 681 | 8 949 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 93 | 246 | 212 | 124 | 242 | 337 | 286 | 317 | 390 | 491 | 1 354 |
| Depreciation & amort. | −35 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 58 | 246 | 212 | 124 | 242 | 337 | 286 | 317 | 390 | 491 | 1 354 |
| Net financials | 207 | 87 | 74 | 79 | −12 | −32 | −34 | −26 | −20 | 50 | 73 |
| Profit before tax | 1 357 | 333 | 285 | 203 | 230 | 305 | 252 | 291 | 370 | 541 | 1 427 |
| Tax | −310 | −77 | −120 | −46 | −51 | −69 | −51 | −66 | −76 | −119 | −314 |
| Net profit | 1 047 | 256 | 165 | 157 | 179 | 236 | 201 | 225 | 294 | 422 | 1 113 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4 497 | 4 731 | 4 994 | 5 372 | 3 234 | 3 888 | 4 508 | 3 114 | 4 304 | 3 730 | 4 905 |
| Equity | 3 657 | 3 913 | 4 078 | 4 235 | 1 214 | 1 450 | 1 651 | 1 876 | 2 169 | 2 591 | 3 704 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 840 | 818 | 916 | 1 137 | 2 020 | 2 438 | 2 857 | 1 238 | 2 135 | 1 139 | 1 201 |
| Total debt | 840 | 818 | 916 | 1 137 | 2 020 | 2 438 | 2 857 | 1 238 | 2 135 | 1 139 | 1 201 |
EBITDA margin
15.1%
This company
15.8%
Market median
+4% vs market
20152025
Equity ratio
75.5%
This company
38.2%
Market median
+98% vs market
20152025
Return on equity
30.0%
This company
18.4%
Market median
+63% vs market
20152025
Net profit margin
12.4%
This company
8.1%
Market median
+53% vs market
20152025
Asset turnover
1.82×
This company
1.12×
Market median
+62% vs market
20152025
Debt / equity
0.32×
This company
0.62×
Market median
+48% vs market
20152025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TE Authorized Recipient of Service | Authorized Recipient of Service | 2022 | — | — |
LA Audit | Audit | 2020 | — | — |
KH Authorized Recipient of Service | Authorized Recipient of Service | 2022 | — | — |
UG Authorized Recipient of Service | Authorized Recipient of Service | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
2CARE4 GROUP APS | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
2CARE4 GROUP APS
2care4 AB (this company)Board members of 2care4 AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tord Elof Ingemar Keinsjö | Authorized Recipient of Service | 0 companies |
| Lars Anders Karlsson | Audit | 0 companies |
| Karl Henrik Björkqvist | Authorized Recipient of Service | 0 companies |
| Ulf Gunne Wedenberg | Authorized Recipient of Service | 0 companies |
| Henrik Jensen | Board of Directors | 0 companies |
| Torben Børsting | Board of Directors | 0 companies |
| Ulrik Ernst Rasmussen | Board of Directors | 0 companies |
| Toke Vaerndal | Chairman | 0 companies |